As Adoption Deepens Among Prescribers, Satisfaction with Gilenya Remains Muted Due to Continuing Issues with Novartis Supp

EXTON, Penn.--(BUSINESS WIRE)-- At six months post launch, market share of Novartis’ Gilenya, the newest disease-modifying agent (DMA) for the treatment of multiple sclerosis (MS), has increased significantly compared to earlier waves of research fielded at one month and three months post-launch. With a nonsignificant increase in physician trial over the past three months, much of the increase in market share is being driven by significant growth in volume per prescriber reflecting deeper adoption within individual practices. The product’s unique oral formulation continues to be perceived as its greatest advantage. Non-prescribers pinpoint concerns over Gilenya’s lack of long-term safety data and issues related to the initiation and monitoring of patients on Gilenya as major obstacles to trial. Overall, satisfaction with Gilenya remains significantly lower than that reported by early adopters one month post-launch. Dissatisfaction seems to be driven by lack of Novartis support, managed care concerns, and safety worries.

The recently released third wave of the LaunchTrends®: Gilenya report series finds that neurologists perceive Gilenya as a second line DMA, following either an efficacy or tolerability failure. Although all DMAs — Biogen Idec’s Avonex and Tysabri, Bayer’s Betaseron, Teva’s Copaxone and Pfizer/EMD Serono’s Rebif — are expected to be impacted by Gilenya switches to some degree, neurologists continue to believe that Avonex and Tysabri are most at risk for cannibalization. The projected share trends for Gilenya remain favorable as surveyed neurologists anticipate a significant increase in use within the next six months. Interestingly, anticipated peak use for Gilenya, which has increased significantly compared to the previous waves, is not significantly different between current prescribers and non-prescribers suggesting that both groups see Gilenya as an important option in their MS treatment armamentarium.

LaunchTrends®: Gilenya is a three wave syndicated report series designed to track the uptake of Novartis’s Gilenya at one month, three months and six months following its commercial availability. In the current wave of research, which measures Gilenya’s market impact at six months post-launch, BioTrends surveyed 76 neurologists and conducted qualitative interviews with a subset of 20 of the respondents in April 2011. BioTrends will continue to track the uptake of Gilenya in the ongoing TreatmentTrends®: Multiple Sclerosis report series, which is published quarterly.

About LaunchTrends

LaunchTrends assesses trial and use of new products, obstacles to use, reasons to use, typical patient types, line of therapy, product perceptions, promotional efforts/messages and product satisfaction.

About BioTrends Research Group, LLC

BioTrends Research Group, LLC provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.



CONTACT:

BioTrends Research Group, LLC
Sharon Funk, 404-223-2963
[email protected]
or
Decision Resources, Inc.
Christopher Comfort, 781-993-2597
[email protected]

KEYWORDS:   United States  North America  Pennsylvania

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Genetics  Pharmaceutical  Other Health  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

After a whirlwind year and two quick-fire raises, cancer startup Black Diamond Therapeutics has nabbed Yumanity, Merck KGaA and SR One veterans to help head up…

In this week's EuroBiotech Report, Lundbeck inks $2 billion Alder buyout, Euro biotechs raise cash and blast rocks Russian smallpox lab.

In our EuroBiotech roundup this week, Nordic Nanovector delays phase 2b readout, PPF buys big Autolus stake and Poxel shares phase 3 diabetes data.